Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05998135 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

StatusRecruiting
PhasePhase 2
Started2023-11-09
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Jun 30, 2026 → Mar 24, 2027
See other at-risk trials from Emory University

Amendment history

2026-10-02
Primary completion pushed: 2026-06-30 → 2027-03-24
Completion pushed: 2027-06-30 → 2028-06-30
2025-09-05
Study Status v3
Primary completion date2025-06-30→2026-06-30
Completion date2026-06-30→2027-06-30
2024-08-06
Study Status v2
Primary completion date2024-06-30→2025-06-30
Completion date2025-06-30→2026-06-30
2024-02-15
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-09-01→confirmed 2023-11-09
Study sitesdetails revised at 1 of 1 site
2023-08-11
Original filing
Emory University
371 trials monitored
See 23 trials at risk
Ovarian Cancer
1,239 trials monitored
See 74 trials at risk
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.
Trial Details
NCT Number NCT05998135
Lead Sponsor Emory University
Collaborators: National Cancer Institute (NCI)
Conditions Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
Enrollment 28 participants
Start Date 2023-11-09
Primary Completion 2027-03-24 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-10-01